Evaluation of spray BIO-max DIM-P in dogs for oral bioavailability and in nu/nu mice bearing orthotopic/metastatic lung tumor models for anticancer activity

Pharmaceutical Research

Volumn 32, Issue 7, 2015, Pages 2292-2300

  Patel, Apurva R ^a   Godugu, Chandraiah ^a   Wilson, Heather ^b   Safe, Stephen ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

anti cancer activity; DIM; dual channel spray drying; enteric coating; self emulsifying drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; DIM P; INDOLE DERIVATIVE; METHANE; UNCLASSIFIED DRUG; EMULSION;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; IN VIVO STUDY; LUNG METASTASIS; MALE; MICROCAPSULE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME; ANIMAL; CHEMISTRY; DOG; DRUG SCREENING; EMULSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; MEDICINAL CHEMISTRY; METABOLISM; METASTASIS; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DOGS; EMULSIONS; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MICE, NUDE; NEOPLASM METASTASIS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930674490     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1620-7     Document Type: Article

References (38)

1. Krishnaiah YSR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Bioavailab. 2010;2010:028-36.
2. Patel AR, Spencer SD, Chougule MB, Safe S, Singh M. Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3′ diindolylmethane (DIM). Eur J Pharm Sci. 2012;46(1-2):8-16.
3. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res. 2009;15(2):543-52.
4. Ichite N, Chougule M, Patel AR, Jackson T, Safe S, Singh M. Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Mol Cancer Ther. 2010;9(11):3003-14.
5. Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21-22):958-65.
6. Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst. 2009;26(5):427-521.
7. Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 2008;355(1-2):269-76.
8. Barakat NS. Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation. J Pharm Pharmacol. 2010;62(2):173-80.
9. Patil P, Patil V, Paradkar A. Formulation of a self-emulsifying system for oral delivery of simvastatin: in vitro and in vivo evaluation. Acta Pharm. 2007;57(1):111-22.
10. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Hong MJ, Jee JP, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72(3):539-45.
11. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13-14):606-12.
12. Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech. 2010;11(1):9-17.
13. Abdalla A, Klein S, Mader K. A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets. Eur J Pharm Sci. 2008;35(5):457-64.
14. Moretti MD, Gavini E, Juliano C, Pirisino G, Giunchedi P. Spray-dried microspheres containing ketoprofen formulated into capsules and tablets. J Microencapsul. 2001;18(1):111-21.
15. Weerakody R, Fagan P, Kosaraju SL. Chitosan microspheres for encapsulation of alpha-lipoic acid. Int J Pharm. 2008;357(1-2):213-8.
16. Parlati C, Colombo P, Buttini F, Young PM, Adi H, Ammit AJ, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res. 2009;26(5):1084-92.
17. Fourie PB, Germishuizen WA, Wong YL, Edwards DA. Spray drying TB vaccines for pulmonary administration. Expert Opin Biol Ther. 2008;8(7):857-63.
18. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverge R. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci. 2003;19(4):273-80.
19. Sou T, Meeusen EN, de Veer M, Morton DA, Kaminskas LM, McIntosh MP. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol. 2011;29(4):191-8.
20. Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith 3rd R, et al. A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes. Mol Cancer Ther. 2004;3(3):247-60.
21. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Lee YI, Kim DD, et al. Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. Int J Pharm. 2009;374(1-2):66-72.
22. Jusko WJ. Guidelines for collection and pharmacokinetic analysis of drug disposition data. In: Evans JJS WE, Jusko WJ, editors. Applied pharmacokinetics. San Francisco: Applied Therapeutics, Inc; 1980.
23. Patel AR, Chougule MB, Lim E, Francis KP, Safe S, Singh M. Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomedicine. 2014;10(5):1053-63.
24. Patel AR, Chougule M, Singh M. EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer. Pharm Res. 2014;29.
25. Patel AR, Chougule MB, I T, Patlolla R, Wang G, Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res. 2013;30(5):1435-46.
26. Hoffmeister CD, Durli TL, Schaffazick SR, Raffin RP, Bender EA, Beck RC, et al. Hydrogels containing redispersible spray-dried melatonin-loaded nanocapsules: a formulation for transdermal-controlled delivery. Nanoscale Res Lett. 2012;7(1):251.
27. Pandit V, Gorantla R, Devi K, Pai R, Sarasija S. Preparation and characterization of pioglitazone cyclodextrin inclusion complexes. J Young Pharm. 2011;3(4):267-74.
28. Mezzena M, Scalia S, Young PM, Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J. 2009;11(4):771-8.
29. Naikwade SR, Bajaj AN, Gurav P, Gatne MM, Singh SP. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSciTech. 2009;10(3):993-1012.
30. Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm. 2011;79(3):635-51.
31. Ge Z, Zhang XX, Gan L, Gan Y. Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability. Acta Pharmacol Sin. 2008;29(8):990-7.
32. Driscoll DF, Nehne J, Peterss H, Franke R, Bistrian BR, Niemann W. The influence of medium-chain triglycerides on the stability of all-in-one formulations. Int J Pharm. 2002;240(1-2):1-10.
33. DeSesso JM LWA. Contrasting the gastrointestinal tracts of mammals: factors that influence absorption. In: Macor J, editor. Annual reports in medicinal chemistry. 1st ed. New York: Academic; 2008. p. 353-71.
34. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm. 2010;76(3):475-85.
35. Lin Y, Shen Q, Katsumi H, Okada N, Fujita T, Jiang X, et al. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats. Biol Pharm Bull. 2007;30(7):1301-7.
36. Trevaskis NL, McEvoy CL, McIntosh MP, Edwards GA, Shanker RM, Charman WN, et al. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Pharm Res. 2010;27(5):878-93.
37. Zhang Z, Ma L, Jiang S, Liu Z, Huang J, Chen L, et al. A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor. J Control Release. 2013;166(1):30-7.
38. Scott Swenson E, Curatolo WJ. (C) Means to enhance penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv Rev. 1992;8(1):39-92.